快速进展的痴呆症在tacrolimus神经毒性:罕见但可逆的痴呆症
Siddharth Chand1, Riya Sharma1, Alaipreet Kaur2
1Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh (PGIMER), Chandigarh, India.
概括
塔克罗利木斯的免疫抑制可以引起神经毒性,即使在正常的血液水平下,也会呈现出快速进展的痴呆症. 及时怀疑和停止使用塔克罗利斯可以导致完全康复.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
背景情况:
- 塔克罗利马斯是器官移植中的重要免疫抑制剂.
- 神经毒性是一种已知的,尽管多样化的,塔克罗利斯治疗的并发症.
- 免疫抑制药物可以导致大量的患者发病率.
相关概念视频
01:20Desensitization and Tachyphylaxis
2.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.3K
01:26Psychosis: Goals of Pharmacotherapy
217
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
217
01:35Long-term Potentiation
55.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.9K
01:22Alzheimer's Disease: Treatment
266
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
266
01:26Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
01:24Parkinson's Disease: Treatment
394
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
394